{"id":495,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2016-02-11","marketCap":42.821495056152344,"name":"Kineta Inc","phone":"12063780400.0","outstanding":10.619999885559082,"symbol":"KA","website":"https://kinetabio.com/","industry":"Biotechnology"},"price":4.2125,"year":2023,"month":11,"day":8,"weekday":"Wednesday","title":"Market Capitalization and Valuation Metrics of Kineta Inc","date":"2023-11-08","url":"/posts/2023/11/08/KA","content":[{"section":"Market Capitalization","text":"As of the latest available data, the market capitalization of Kineta Inc is $X million."},{"section":"Valuation Ratios","text":"1. Price-to-Earnings Ratio (P/E): The P/E ratio of Kineta Inc is X, indicating the stock's price relative to its earnings. This ratio can be compared to industry benchmarks to assess the stock's valuation."},{"section":"","text":"2. Price-to-Sales Ratio (P/S): The P/S ratio of Kineta Inc is X, which compares the stock's market capitalization to its revenue. This ratio helps in evaluating the stock's valuation relative to industry peers."},{"section":"","text":"3. Price-to-Book Ratio (P/B): The P/B ratio of Kineta Inc is X, comparing the stock's market value to its net assets. This ratio is commonly used for assessing the stock's value relative to its book value and industry averages."},{"section":"","text":"4. Enterprise Value-to-Revenue Ratio (EV/R): The EV/R ratio of Kineta Inc is X, comparing the enterprise value of the company to its revenue. This ratio helps determine the stock's valuation considering its total value, including debt and equity."},{"section":"","text":"5. Enterprise Value-to-EBITDA Ratio (EV/EBITDA): The EV/EBITDA ratio of Kineta Inc is X, which compares the enterprise value to the company's EBITDA. This ratio is often used to assess the stock's valuation and potential for acquisition."},{"section":"","text":"6. Dividend Yield: Kineta Inc does not currently offer a dividend, thus the dividend yield is zero. This ratio is meaningful for income-seeking investors."},{"section":"","text":"7. Return on Equity (ROE): The ROE of Kineta Inc is X%, indicating the company's profitability relative to its shareholders' equity. This metric can be compared to industry averages to evaluate the company's performance."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1699351200,"headline":"KA: Third Quarter Results","id":123693293,"image":"https://media.zenfs.com/en/scr.zacks.com/606a28697f77945437d4f71246504dce","symbol":"KA","publisher":"Yahoo","summary":"By John Vandermosten, CFA NASDAQ: KA READ THE FULL KA RESEARCH REPORT 3Q:23 Financial and Operational Results Since our last report less than a month ago, Kineta, Inc. (NASDAQ: KA), has reported its third quarter financial and operational results, dosed its first combination therapy patient in its Phase I/II VISTA-101 clinical trial and presented two posters at SITC for its anti-CD27 and","url":"https://finance.yahoo.com/news/ka-third-quarter-results-100000046.html"},{"category":"company","date":1699349160,"headline":"Buy Rating for Kineta Backed by Promising Drug Trials and Solid Financial Performance","id":123700452,"image":"","symbol":"KA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3199794812"},{"category":"company","date":1699277400,"headline":"Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting","id":123658627,"image":"https://s.yimg.com/ny/api/res/1.2/E9WO47luryyrcwDXbyhuiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNTQ-/https://media.zenfs.com/en/globenewswire.com/41360a647daef13bc17a2394954a648b","symbol":"KA","publisher":"Yahoo","summary":"Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional Pharmacokinetics Biomarker Results Demonstrate Robust VISTA Target Engagement Additional Monotherapy and Combination Therapy Clinical Data Anticipated in Q2 2024 SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer","url":"https://finance.yahoo.com/news/kineta-unveils-positive-data-vista-133000992.html"},{"category":"company","date":1699256700,"headline":"Kineta announces new data from VISTA-101 trial of KVA12123","id":123659373,"image":"","symbol":"KA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3197577172"},{"category":"company","date":1699101647,"headline":"Kineta Insider Purchases Yet To Pay Off Regardless Of Recent Strength","id":123638103,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"KA","publisher":"Yahoo","summary":"Insiders who bought US$487.3k worth of Kineta, Inc. ( NASDAQ:KA ) stock in the last year recovered part of their losses...","url":"https://finance.yahoo.com/news/kineta-insider-purchases-yet-pay-124047000.html"},{"category":"company","date":1699041660,"headline":"Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update","id":123601511,"image":"https://s.yimg.com/ny/api/res/1.2/E9WO47luryyrcwDXbyhuiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNTQ-/https://media.zenfs.com/en/globenewswire.com/41360a647daef13bc17a2394954a648b","symbol":"KA","publisher":"Yahoo","summary":"Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors Initial KVA12123 monotherapy clinical safety, pharmacokinetic, receptor occupancy and biomarker data to be presented at SITC 2023 Expected Cash Runway into early 2025 SEATTLE, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused","url":"https://finance.yahoo.com/news/kineta-reports-third-quarter-2023-200100064.html"},{"category":"company","date":1699041600,"headline":"Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting","id":123601512,"image":"https://s.yimg.com/ny/api/res/1.2/E9WO47luryyrcwDXbyhuiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNTQ-/https://media.zenfs.com/en/globenewswire.com/41360a647daef13bc17a2394954a648b","symbol":"KA","publisher":"Yahoo","summary":"Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumor Efficacy as a Single Agent and in Combination with Checkpoint Inhibitors in Solid and Hematological Tumor Models SEATTLE, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer imm","url":"https://finance.yahoo.com/news/kineta-presents-preclinical-data-lead-200000629.html"},{"category":"company","date":1698983100,"headline":"Kineta files to sell 890K shares of common stock for holders","id":123605367,"image":"","symbol":"KA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3194429626"},{"category":"company","date":1698981300,"headline":"Kineta GAAP EPS of -$0.46 beats by $0.09","id":123605370,"image":"","symbol":"KA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3194377500"}]}